<DOC>
	<DOCNO>NCT01530334</DOCNO>
	<brief_summary>primary objective characterise impact gefitinib Response Evaluation Criteria Solid Tumours ( RECIST ) base assessment ; objective response rate ( ORR ; confirm complete response ( CR ) partial response ( PR ) ) disease control rate ( DCR ; confirm complete response ( CR ) partial response ( PR ) stable disease ( SD ) ) patient EGFR M+ NSCLC</brief_summary>
	<brief_title>Iressa Re-Challenge Advanced NSCLC EGFR M+ Patients Who Responded Gefitinib USed 1st Line Previous Treatment</brief_title>
	<detailed_description>A phase II Open Label , Multicentre , Single Arm Study Characterise Efficacy , Safety Tolerability Gefitinib 250 mg ( IRESSA� ) 3rd line treatment re-challenge Patients , Epidermal Growth Factor Receptor ( EGFR ) Mutation Positive Locally Advanced Metastatic Non-Small Cell Lung Cancer ( NSCLC ) respond gefitinib 1st line progress 2nd line chemotherapy</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Gefitinib</mesh_term>
	<criteria>Inclusion Criteria screening ( Visit 1 ) Start Study Treatment ( Visit 2 ) : Provision inform consent prior study specific procedure . Histologically cytologically confirm NSCLC activate sensitise EGFR TK mutation determine start first gefitinib treatment use wellvalidated robust methodology : adenocarcinoma , include Bronchoalveolar Carcinoma ( BAC ) , squamous cell carcinoma , large cell carcinoma , adenosquamous carcinoma undifferentiated carcinoma nototherwise specify NSCLC . Female male patient age 18 year Locally advance metastatic stage IIIB/IV disease , suitable therapy curative intent stage IV ( metastatic ) disease , eligible gefitinib rechallenge treatment NSCLC already receive gefitinib document complete ( CR ) partial response ( PR ) stable disease ( SD ) &gt; 12 week best response 1st gefitinib treatment progress subsequent anticancer therapy ( exclude EGFRTKIs ) treatment , include limited doublet platinum base chemotherapy docetaxel monotherapy pemetrexed monotherapy . Measurable disease define least one lesion , previously irradiate , accurately measure baseline ≥ 10 mm long diameter ( except lymph node must short axis ≥ 15 mm ) spiral CT MRI suitable accurate repeat measurement . WHO / ECOG / Zubrod performance status 02 . Known severe hypersensitivity gefitinib excipients product Prior EGFR TKIs except gefitinib follow subsequent anticancer treatment ( include chemotherapy exclude EGFRTKIs ) . Previous adjuvant chemotherapy allow . Prior surgery radiotherapy must complete 6 month start study treatment . Palliative radiotherapy must complete least 4 week start study treatment persistent radiation toxicity . Progression disease stable disease ( SD ) &lt; 12 week best response 1st line treatment gefitinib Not progress last anticancer treatment . Considered require radiotherapy lung time study entry near future Past medical history interstitial lung disease , druginduced interstitial disease , radiation pneumonitis require steroid treatment evidence clinically active interstitial lung disease Preexisting idiopathic pulmonary fibrosis evidence CT scan baseline Insufficient lung function determine either clinical examination arterial oxygen tension ( PaO2 ) &lt; 70 Torr Known suspect brain metastasis spinal cord compression , unless treat surgery and/or radiation stable without steroid treatment least 4 week prior first dose study medication Any unresolved chronic toxicity great CTC grade 2 previous anticancer therapy Concomitant use know CYP 3A4 inducer phenytoin , carbamazepine , rifampicin , barbiturate , St John 's Wort Pregnancy breastfeed As judged investigator , evidence severe uncontrolled systemic disease ( eg , unstable uncompensated respiratory , cardiac , hepatic , renal disease ) Evidence significant clinical disorder laboratory find make undesirable patient participate study Other coexist malignancy malignancy diagnose within last 5 year exception basal cell carcinoma cervical cancer situ Life expectancy le 12 week</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>130 Years</maximum_age>
	<verification_date>January 2016</verification_date>
</DOC>